Researchers are presenting new clinical data at the forthcoming CHEST Annual Meeting in Los Angeles, on a minimally invasive technology to aid in the early detection and preparation for treatment of Lung Cancer.
Lung cancer remains the number one cancer-related killer amongst men and women, and can impact anyone regardless of age or smoking history. Sadly, the disease is often caught in later stages, when patient outcomes are usually far less favorable.
Research has shown that early detection and treatment of cancer has the potential to significantly improve patient outcomes and potentially save millions of lives worldwide.
In a major step forward in the early detection of lung cancer, researchers are presenting new data from a landmark global clinical trial on a minimally invasive technology to aid in the early detection and preparation for treatment of this deadly disease.
The solution in question, called the superDimension™ navigation system, uses LungGPS™ technology, the first of its kind to enable Electromagnetic Navigation Bronchoscopy (ENB) procedures. The GPS technology allows physicians to proactively chart out their approach to biopsy lesions that exist in the peripheral lungs.
Clinical data will be presented on the interim results of the NAVIGATE (Clinical Evaluation of superDimension™ Navigation System™ for Electromagnetic Navigation Bronchoscopy) study— the largest ever prospective, global multicenter clinical study to date on ENB using the system.
Lead investigators will share early findings at CHEST from the first 500 patients on how superDimension™ navigation system use during ENB procedures provides physicians guided navigation and extended reach, allowing them to access small tumors and safely take tissue samples from the peripheral lung for diagnoses.
The presentation will take place at the CHEST Annual Meeting next Tuesday, October 25th, at 8:45 AM PT